Marina Chiara Garassino to Clinical Trials as Topic
This is a "connection" page, showing publications Marina Chiara Garassino has written about Clinical Trials as Topic.
Connection Strength
0.142
-
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori. 2018 Mar-Apr; 104(2):88-95.
Score: 0.027
-
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J. 2018 02; 51(2).
Score: 0.027
-
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? Tumori. 2016 Jan-Feb; 102(1):18-30.
Score: 0.023
-
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015 May; 94(2):213-27.
Score: 0.022
-
Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res. 2011 May 06; 30:50.
Score: 0.017
-
Predicting response of molecular targeted therapies: a still possible challenge? Ann Oncol. 2008 May; 19(5):829-30.
Score: 0.014
-
New anti-emetic treatments. Ann Oncol. 2007 Jul; 18 Suppl 9:ix43-7.
Score: 0.013